CA2123593C - Methode de traitement de l'inflammation dependante du tnf a l'aide d'antagonistes du facteur de necrose tumorale - Google Patents

Methode de traitement de l'inflammation dependante du tnf a l'aide d'antagonistes du facteur de necrose tumorale Download PDF

Info

Publication number
CA2123593C
CA2123593C CA002123593A CA2123593A CA2123593C CA 2123593 C CA2123593 C CA 2123593C CA 002123593 A CA002123593 A CA 002123593A CA 2123593 A CA2123593 A CA 2123593A CA 2123593 C CA2123593 C CA 2123593C
Authority
CA
Canada
Prior art keywords
tnf
tnfr
pro
ser
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002123593A
Other languages
English (en)
Other versions
CA2123593A1 (fr
Inventor
Craig A. Smith
Cindy A. Jacobs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25484181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2123593(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of CA2123593A1 publication Critical patent/CA2123593A1/fr
Application granted granted Critical
Publication of CA2123593C publication Critical patent/CA2123593C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Procédé de traitement de maladies inflammatoires dépendantes du TNF chez un mammifère, consistant à administrer un antagoniste du TNF, tel qu'un récepteur de TNF soluble.
CA002123593A 1992-09-15 1993-09-14 Methode de traitement de l'inflammation dependante du tnf a l'aide d'antagonistes du facteur de necrose tumorale Expired - Lifetime CA2123593C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94623692A 1992-09-15 1992-09-15
US07/946,236 1992-09-15
PCT/US1993/008666 WO1994006476A1 (fr) 1992-09-15 1993-09-14 Procede de traitement de l'inflammation dependante du facteur necrosant des tumeurs malignes (tnf) a l'aide d'antagonistes dudit tnf

Publications (2)

Publication Number Publication Date
CA2123593A1 CA2123593A1 (fr) 1994-03-31
CA2123593C true CA2123593C (fr) 2000-03-14

Family

ID=25484181

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002123593A Expired - Lifetime CA2123593C (fr) 1992-09-15 1993-09-14 Methode de traitement de l'inflammation dependante du tnf a l'aide d'antagonistes du facteur de necrose tumorale

Country Status (8)

Country Link
EP (1) EP0620739A4 (fr)
JP (1) JPH07504203A (fr)
KR (1) KR100232688B1 (fr)
AU (1) AU670125B2 (fr)
CA (1) CA2123593C (fr)
NO (1) NO941780L (fr)
NZ (1) NZ256293A (fr)
WO (1) WO1994006476A1 (fr)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE289350T1 (de) 1989-04-21 2005-03-15 Amgen Inc Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
WO1993019777A1 (fr) * 1992-03-30 1993-10-14 Immunex Corporation Proteines de fusion comprenant un recepteur de facteur de necrose tumorale
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
WO1996003141A1 (fr) * 1994-07-22 1996-02-08 F. Hoffmann-La Roche Ag Compositions pharmaceutiques comprenant une proteine chimere liant le facteur de necrose tumorale
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US6254870B1 (en) * 1995-02-03 2001-07-03 G. D. Searle & Co. Thrombopoietin: IL-3 fusion protein
IL112834A (en) * 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
WO1997003686A1 (fr) * 1995-07-14 1997-02-06 Applied Research Systems Recepteur de tnf et hormone steroïdienne en therapie combinee
US7012060B1 (en) 1995-07-14 2006-03-14 Applied Research Systems Ars Holding N.V. TNF receptor and steroid hormone in a combined therapy
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
JP2000510113A (ja) * 1996-05-08 2000-08-08 エフ・ホフマン―ラ ロシュ アーゲー ＴＮＦＲ―Ｉｇによる喘息の治療
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
AU5696198A (en) * 1996-12-06 1998-06-29 Amgen, Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
SI0942740T1 (en) * 1996-12-06 2003-12-31 Amgen Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
WO1998051344A1 (fr) * 1997-05-12 1998-11-19 The Kennedy Institute Of Rheumatology Suppression therapeutique du facteur de necrose tumorale alpha et du facteur de croissance des cellules endotheliales vasculaires
AU8492598A (en) * 1997-07-17 1999-02-10 Regents Of The University Of Michigan, The Methods and compositions for tumor reduction
WO2000002902A1 (fr) * 1998-07-13 2000-01-20 Gill Parkash S Nouveaux inhibiteurs de l'angiogenese et de la croissance tumorale
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1206275B1 (fr) * 1998-11-05 2007-09-05 Omeros Corporation Solution d'irrigation et methode pour l'inhibition de la douleur et de l'inflammation
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
IL127851A0 (en) * 1998-12-30 1999-10-28 Applied Research Systems Inhibition of TNF activity
EP1022027A1 (fr) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Antagonistes du TNF (Tumor necrosis factor) et leurs utilisations contre l'endometriose
CA2365824A1 (fr) * 1999-04-02 2000-10-12 F. Ann Hayes Utilisation d'un recepteur du facteur de necrose tumorale soluble dans le traitement de l'insuffisance cardiaque
EP1180159B1 (fr) 1999-05-28 2008-09-03 Targeted Genetics Corporation Techniques et compositions permettant d'abaisser le niveau de facteur de necrose tumorale (tnf) dans les troubles associes au tnf
EP1939300A1 (fr) * 1999-05-28 2008-07-02 Targeted Genetics Corporation Procédés et compositions pour diminuer le niveau de facteur de nécrose de tumeur (TNF) pour des troubles associés au TNF
US6627199B1 (en) 1999-07-09 2003-09-30 Amgen Inc Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family
KR20080099355A (ko) * 1999-07-21 2008-11-12 오메로스 코포레이션 동통, 염증 및 연골 퇴화를 억제하기 위한 용액 및 억제방법
US6521422B1 (en) 1999-08-04 2003-02-18 Amgen Inc. Fhm, a novel member of the TNF ligand supergene family
AU6517800A (en) 1999-08-04 2001-03-05 Amgen, Inc. Ntr3, a member of the tnf-receptor supergene family
GB9927681D0 (en) * 1999-11-23 2000-01-19 Glaxo Group Ltd Protein
KR20020097241A (ko) 2000-05-04 2002-12-31 에이브이아이 바이오파마 인코포레이티드 스플라이스-영역 안티센스 조성물 및 방법
CA2385745C (fr) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methodes pour administrer des anticorps anti-tnf.alpha.
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040219142A1 (en) 2002-07-19 2004-11-04 Abbott Laboratories S.A. Treatment of skin and nail disorders using TNFalpha inhibitors
US20060140933A1 (en) * 2002-08-16 2006-06-29 Wyeth And Imperial College Innovations Limited Compositions and methods for treating rage-associated disorders
EP1546329A4 (fr) * 2002-09-13 2006-07-12 Univ Queensland Systeme d'expression genique fonde sur une efficacite de translation de codon
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
KR20050105486A (ko) * 2003-02-28 2005-11-04 아레스 트레이딩 에스.에이. 종양괴사인자-결합 단백질의 액상 제제
EP1688439A4 (fr) * 2003-10-08 2007-12-19 Kyowa Hakko Kogyo Kk Composition proteique hybride
TWI556829B (zh) 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
EP1817340B1 (fr) * 2004-11-12 2012-05-16 Xencor, Inc. Variants fc presentant une liaison modifiee au fcrn
AU2006230419A1 (en) * 2005-03-31 2006-10-05 Targeted Genetics Corporation Methods for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
EP2500037A3 (fr) 2005-05-16 2012-10-24 Abbott Biotechnology Ltd Utilisation d'un inhibiteur de TNF alpha pour traiter la polyarthrite érosive
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
CA2626804A1 (fr) 2005-11-01 2007-08-09 Abbott Biotechnology Ltd. Methodes et compositions de diagnostic de la spondylarthrite ankylosante a l'aide de biomarqueurs
US7785834B2 (en) 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
WO2007109686A2 (fr) 2006-03-20 2007-09-27 University Of Pittsburgh Immunomodulation de conditions inflammatoires en utilisant la protéine 1 apparentée à la follistatine et des agents se liant à celle-ci
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
RU2466740C2 (ru) 2006-04-05 2012-11-20 Эбботт Байотекнолоджи Лтд. Очистка антитела
EP2708242A3 (fr) 2006-04-10 2014-03-26 Abbott Biotechnology Ltd Utilisations et compositions pour le traitement de la spondylarthrite ankylosante
CA2564435A1 (fr) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methodes de controle et de traitement des troubles intestinaux
WO2008063213A2 (fr) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Compositions destinées au traitement de la polyarthrite psoriasique et leurs applications
KR101396797B1 (ko) 2006-06-30 2014-05-26 애브비 바이오테크놀로지 리미티드 자동 주사 장치
ES2755386T5 (es) 2006-08-28 2023-04-05 Ares Trading Sa Proceso para la purificación de proteínas que contienen fragmentos Fc
CA2661872A1 (fr) * 2006-08-28 2008-03-06 Ares Trading S.A. Procede de purification de proteines fc-hybrides
JP2010501622A (ja) * 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Ｆｃ−融合タンパク質の精製法
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
CA2666934A1 (fr) 2006-10-20 2008-04-24 Biogen Idec Ma Inc. Traitement des troubles de demyelinisation avec un recepteur soluble de la lymphotoxine-beta
CA2666981A1 (fr) * 2006-10-20 2008-05-02 Ercole Biotech, Inc. Recepteurs de tnf solubles et leur utilisation pour le traitement de maladies
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
EP2679996A1 (fr) 2007-05-31 2014-01-01 AbbVie Inc. Biomarqueurs prédictifs de la réactivité aux inhibiteurs TNF-alfa dans des troubles auto-immuns
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
KR101361355B1 (ko) 2007-06-14 2014-02-12 갈락티카 파마슈티칼스, 인크. Ｒａｇｅ 융합 단백질
EP2072527A1 (fr) 2007-12-21 2009-06-24 Altonabiotec AG Procédé et système pour fournir des services de communications sur un terminal mobile, et terminal mobile
US8658379B2 (en) 2008-01-29 2014-02-25 University of Pittsburgh—of the Commonwealth System of Higher Education Follistatin-like protein-1 as a biomarker for sepsis
AU2009280913A1 (en) * 2008-08-12 2010-02-18 Avesthagen Limited An expression vector and a method thereof
US20110251099A1 (en) 2008-12-30 2011-10-13 Sudha Visvanathan SERUM MARKERS PREDICTING CLINICAL RESPONSE TO ANTI-TNFa ANTIBODIES IN PATIENTS WITH ANKYLOSING SPONDYLITIS
MX2011011541A (es) 2009-04-29 2012-02-28 Abbott Biotech Ltd Dispositivo de inyeccion automatico.
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
WO2011068993A1 (fr) 2009-12-02 2011-06-09 Acceleron Pharma Inc. Compositions et procédés pour augmenter la demi-vie sérique de protéines de fusion fc
CA2781725A1 (fr) 2009-12-16 2011-06-23 Philip Bosch Procedes de traitement de la cystite interstitielle
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
MA33989B1 (fr) 2010-01-15 2013-02-01 Kirin Amgen Inc Formulation d'anticorps et régimes thérapeutiques
WO2011097301A2 (fr) 2010-02-02 2011-08-11 Abbott Biotechnology Ltd. Procédés et compositions de prédiction de la réponse à un traitement avec un inhibiteur du tnf-α
WO2011133823A1 (fr) 2010-04-21 2011-10-27 Abbott Biotechnology Ltd. Dispositif d'injection automatique portable pour l'administration contrôlée d'agents thérapeutiques
WO2011146727A1 (fr) 2010-05-19 2011-11-24 Philip Bosch Méthodes de traitement de la cystite interstitielle
WO2011153477A2 (fr) 2010-06-03 2011-12-08 Abbott Biotechnology Ltd. Utilisations et compositions pour le traitement de l'hidrosadénite (hs)
FR2962335B1 (fr) 2010-07-12 2013-01-18 Cll Pharma Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives
WO2012019099A2 (fr) 2010-08-05 2012-02-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Protéine 1 analogue à la follistatine utilisable en tant que biomarqueur des troubles inflammatoires
EP2667918B1 (fr) 2011-01-24 2017-03-01 AbbVie Biotechnology Ltd Dispositifs d'injection automatique avec surfaces de prehension surmoulées
BR112013023967A2 (pt) 2011-03-18 2016-01-19 Abbvie Inc sistemas, dispositivos e métodos para a montagem de dispositivos de injeção automática e subconjuntos dos mesmos
CN105413022A (zh) 2011-03-29 2016-03-23 艾伯维公司 自动注射装置中的改进的护罩展开
CN107096098A (zh) 2011-04-21 2017-08-29 艾伯维公司 可佩戴式自动注射装置
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
WO2012170938A1 (fr) 2011-06-08 2012-12-13 Acceleron Pharma Inc. Compositions et procédés pour augmenter la demi-vie sérique
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
RS59179B1 (sr) 2011-10-18 2019-10-31 Coherus Biosciences Inc Formulacije etanercepta stabilizovane jonima magnezijuma
KR101525919B1 (ko) * 2012-05-11 2015-06-03 가톨릭대학교 산학협력단 자가면역 질환 예방 및 치료를 위한 ｔｎｆｒ２를 기반으로 하는 이중 항체
JP2015533797A (ja) 2012-09-11 2015-11-26 コヒラス・バイオサイエンシズ・インコーポレイテッド 高純度および優れた収率の正確に折り畳まれたエタネルセプト
ES2760002T3 (es) 2014-03-31 2020-05-12 Amgen K A Inc Métodos de tratamiento de la psoriasis de uñas y cuero cabelludo
US20170183376A1 (en) 2014-06-24 2017-06-29 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
JP6885875B2 (ja) 2014-12-22 2021-06-16 アレス トレーディング ソシエテ アノニム 液体医薬組成物
EP3078675A1 (fr) 2015-04-10 2016-10-12 Ares Trading S.A. Régime de dosage à induction pour le traitement des maladies liées au tnf alpha
AU2017248354A1 (en) 2016-04-08 2018-10-04 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
EP3257866A1 (fr) 2016-06-17 2017-12-20 Academisch Medisch Centrum Anticorps anti-tnf modifiés et leur utilisation dans le traitement de la maladie intestinale inflammatoire
CN110430801A (zh) 2016-12-14 2019-11-08 普罗根尼蒂公司 使用tnf抑制剂治疗胃肠道疾病
JOP20190162A1 (ar) 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
EP3810095A1 (fr) 2018-06-20 2021-04-28 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur du tnf
CN112654350A (zh) 2018-07-03 2021-04-13 诺华股份有限公司 使用nlrp3拮抗剂治疗对tnf抑制剂有抗性的受试者或针对所述患者选择治疗的方法
SG11202101674QA (en) 2018-08-29 2021-03-30 Regeneron Pharma Methods and compositions for treating subjects having rheumatoid arthritis
TW202043285A (zh) 2019-01-31 2020-12-01 法商賽諾菲生物技術公司 用於治療幼年原發性關節炎之組成物及方法
CN110964119A (zh) * 2019-12-05 2020-04-07 沣潮医药科技（上海）有限公司 抗疟二聚体免疫粘附素、药物组合物和用途
EP4261222A1 (fr) 2020-12-09 2023-10-18 HK inno.N Corporation ANTICORPS ANTI-OX40L, ANTICORPS BISPÉCIFIQUE ANTI-OX40L/ANTI-TNFalpha ET LEURS UTILISATIONS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
CA2065346C (fr) * 1989-09-05 2005-03-29 Craig A. Smith Recepteurs .alpha. et .beta. de facteur de necrose tumorale
EP0567566B2 (fr) * 1991-01-18 2007-07-04 Amgen Inc., Procedes pour traiter les maladies induites par facteur de necrose tumorale
WO1994006431A1 (fr) * 1992-09-22 1994-03-31 Cell Therapeutics, Inc. Nouveaux composes epoxy

Also Published As

Publication number Publication date
NO941780D0 (no) 1994-05-11
AU670125B2 (en) 1996-07-04
NZ256293A (en) 1997-06-24
NO941780L (no) 1994-07-15
JPH07504203A (ja) 1995-05-11
KR100232688B1 (ko) 1999-12-01
WO1994006476A1 (fr) 1994-03-31
AU4920993A (en) 1994-04-12
CA2123593A1 (fr) 1994-03-31
EP0620739A4 (en) 1997-01-15
EP0620739A1 (fr) 1994-10-26

Similar Documents

Publication Publication Date Title
CA2123593C (fr) Methode de traitement de l'inflammation dependante du tnf a l'aide d'antagonistes du facteur de necrose tumorale
US5605690A (en) Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
AU630497B2 (en) Tumor necrosis factor-alpha and -beta receptors
USRE36755E (en) DNA encoding tumor necrosis factor-α and -β receptors
US6541610B1 (en) Fusion proteins comprising tumor necrosis factor receptor
US5712155A (en) DNA encoding tumor necrosis factor-α and -β receptors
EP0670730B1 (fr) Proteine de fusion comprenant deux recepteurs du facteur de necrose tumorale
AU646695B2 (en) Isolated viral protein cytokine antagonists
US5945397A (en) Purified p75 (type II) tumor necrosis factor receptor polypeptides
US7700318B2 (en) Chimeric polypeptide and use thereof
US20050042228A1 (en) Method and pharmaceutical composition for the treatment of immune disorders
IE911108A1 (en) Isolated Viral Protein Cytokine Antagonists
NZ280051A (en) Tnf-r dimers (tumour necrosis factor - receptor), dna coding for same and vectors including the dna

Legal Events

Date Code Title Description
EEER Examination request